The DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.
Analysis of nanoparticle delivery to tumours
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, they used a non-standard metric for tumor delivery defined as percent injected dose (%ID) in tumor = (AUCtumor/tend)*tumor mass.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [241]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chan W.C.W and coworkers performed a study analyzing the nanomedicine delivery literature from the year 2005 to 2015 and exhibited that only 0.7% NPs that were administered systemically reach tumors [160].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [160]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“recent reports have revealed only a modest increase in tumor targeting when this approach is applied”
From Cloaking nanoparticles with protein corona shield for targeted drug delivery. (2018) · cites this paper as [8]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“the addition of targeting ligands increased the clearance of nanoparticles by MPS”
From Cloaking nanoparticles with protein corona shield for targeted drug delivery. (2018) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“A cancer-nanomedicine repository (http://inbs.med.utoronto.ca/cgi-bin/Repository.cgi) spearheaded by the University of Toronto enables researchers to share their own experimental data, and has allowed for the determination of the delivery efficiency of specific nanomaterials into tumours46.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
Cancer Cell Imaging and Photothermal Therapy in the Near-Infrared Region by Using Gold Nanorods
Huang, X., El‐Sayed, I. H., Qian, W. P., & El‐Sayed, M. A. (2006) · Journal of the American Chemical Society · doi:10.1021/ja057254a · Cited by 5,442
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Flagged first, then by citations
1 of the 125 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Dvorak, H. F. in The Endothelium: A Comprehensive Reference (ed. Aird, W. ) 1457–1470 (Cambridge Univ. Press, 2007).
Cited by
Sorted by citations
Items 101–149 of 149
Mesoporous Silica Nanoparticles as Drug Delivery Vehicles in Cancer
Watermann, A., & Brieger, J. (2017) · Nanomaterials · doi:10.3390/nano7070189 · Cited by 404
Cheng, G., Li, W., Ha, L., Han, X., Hao, S., Wan, Y., Wang, Z., Dong, F., Zou, X., Mao, Y., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b03584 · Cited by 371
A versatile drug delivery system targeting senescent cells
Muñoz‐Espín, D., Rovira, M., Galiana, I., Giménez, C., Lozano‐Torres, B., Paez‐Ribes, M., Llanos, S., Chaib, S., Muñoz‐Martín, M., Ucero, A. C., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809355 · Cited by 339
Breaking Down the Barriers to Precision Cancer Nanomedicine
von Roemeling, C., Jiang, W., Chan, C. K., Weissman, I. L., & Kim, B. Y. S. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.07.006 · Cited by 330
Targeting 3D Bladder Cancer Spheroids with Urease-Powered Nanomotors
Hortelão, A. C., Carrascosa, R., Murillo-Cremaes, N., Patiño, T., & Sánchez, S. (2019) · ACS Nano · doi:10.1021/acsnano.8b06610 · Cited by 287
Engineering and physical sciences in oncology: challenges and opportunities
Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273
Metallodrugs in cancer nanomedicine
Peña, Q., Wang, A., Zaremba, O., Shi, Y., Scheeren, H. W., Metselaar, J. M., Kiessling, F., Pallares, R. M., Wuttke, S., & Lammers, T. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00468a · Cited by 259
Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01605-4 · Cited by 259
Enhancing tumor penetration of nanomedicines
Sun, Q., Ojha, T., Kiessling, F., Lammers, T., & Shi, Y. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00068 · Cited by 198
Xiao, W., Wang, Y., Zhang, H., Liu, Y., Xie, R., He, X., Zhou, Y., Liang, L., & Gao, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120888 · Cited by 174
Ioannidis, J. P. A., Kim, B. Y. S., & Trounson, A. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0314-y · Cited by 175
Maeda, H. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030229 · Cited by 167
The in vivo fate of polymeric micelles
Cai, Y., Qi, J., Lu, Y., He, H., & Wu, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114463 · Cited by 154
Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy
Dunne, M., Regenold, M., & Allen, C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.007 · Cited by 150
Chen, B., Dai, W., Mei, D., Liu, T., Li, S., He, B., He, B., Yuan, L., Zhang, H., Wang, X., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.014 · Cited by 142
Ultrasensitive tumour-penetrating nanosensors of protease activity
Kwon, E. J., Dudani, J. S., & Bhatia, S. N. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0054 · Cited by 131
Cancer-on-a-chip systems at the frontier of nanomedicine
Zhang, Y. S., Zhang, Y.-N., & Zhang, W. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.011 · Cited by 127
Evaluation of nanomedicines: stick to the basics
McNeil, S. E. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.73 · Cited by 126
A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics
Price, L. S. L., Stern, S. T., Deal, A. M., Kabanov, A. V., & Zamboni, W. C. (2020) · Science Advances · doi:10.1126/sciadv.aay9249 · Cited by 128
Combination therapy based on nano codelivery for overcoming cancer drug resistance
Wang, H., & Huang, Y. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100024 · Cited by 115
Nanoparticle Interactions with the Tumor Microenvironment
Huai, Y., Hossen, M. N., Wilhelm, S., Bhattacharya, R., & Mukherjee, P. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00448 · Cited by 113
Self-citationThe Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery
Kularatne, R. N., Crist, R. M., & Stern, S. T. (2022) · Pharmaceuticals · doi:10.3390/ph15070897 · Cited by 109
Light Triggered Oxygen-Affording Engines for Repeated Hypoxia-Resistant Photodynamic Therapy
Zhou, T.-J., Xing, L., Fan, Y.-T., Cui, P.-F., & Jiang, H.-L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.016 · Cited by 104
Ho, Y. T., Kamm, R. D., & Kah, J. C. Y. (2018) · Nanoscale · doi:10.1039/c8nr02393j · Cited by 102
Mapping of Molecular Structure of the Nanoscale Surface in Bionanoparticles
Herda, L. M., Hristov, D. R., Lo Giudice, M. C., Polo, E., & Dawson, K. A. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b12297 · Cited by 100
Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030389 · Cited by 98
“7% NPs that were administered systemically reach tumors [160].”
BackgroundHarnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy
Chen, S., Lai, S. W. T., Brown, C. E., & Feng, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635173 · Cited by 91
“However, a significant barrier for using nanoparticles is the fact that despite being able extravasate and persist due to EPR, only a very small percentage (less than 1%) of injected nanoparticles are actually able to traffic and be delivered to their intended destination (130, 131).”
BackgroundKhalin, I., Heimburger, D., Melnychuk, N., Collot, M., Groschup, B., Hellal, F., Reisch, A., Plesnila, N., & Klymchenko, A. S. (2020) · ACS Nano · doi:10.1021/acsnano.0c01505 · Cited by 82
Enabling peristalsis of human colon tumor organoids on microfluidic chips
Fang, G., Lu, H., Al-Nakashli, R., Chapman, R., Zhang, Y., Ju, L. A., Lin, G., Stenzel, M. H., & Jin, D. (2022) · Biofabrication · doi:10.1088/1758-5090/ac2ef9 · Cited by 77
Prediction of anti-cancer nanotherapy efficacy by imaging
Miller, M. A., Arlauckas, S., & Weissleder, R. (2017) · Nanotheranostics · doi:10.7150/ntno.20564 · Cited by 74
Cao, C., Zhao, J., Lu, M., Garvey, C. J., & Stenzel, M. H. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.8b01707 · Cited by 72
Yu, J. H., Steinberg, I., Davis, R. M., Malkovskiy, A. V., Zlitni, A., Radzyminski, R. K., Jung, K. O., Chung, D. T., Curet, L. D., D’Souza, A. L., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c07470 · Cited by 67
Improving nanotherapy delivery and action through image-guided systems pharmacology
Ng, T. S. C., Garlin, M. A., Weissleder, R., & Miller, M. A. (2020) · Theranostics · doi:10.7150/thno.37215 · Cited by 60
Gao, W., Ye, G., Duan, X., Yang, X., & Yang, V. C. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s115215 · Cited by 57
Zhang, Y., Chen, R., Liu, F., Miao, P., Lin, L., & Ye, J. (2023) · Small Methods · doi:10.1002/smtd.202201334 · Cited by 52
Bilynsky, C., Millot, N., & Papa, A. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10256 · Cited by 52
Rapid Assessment of Nanoparticle Extravasation in a Microfluidic Tumor Model
Vu, M. N., Rajasekhar, P., Poole, D. P., Khor, S. Y., Truong, N. P., Nowell, C. J., Quinn, J. F., Whittaker, M., Veldhuis, N. A., & Davis, T. P. (2019) · ACS Applied Nano Materials · doi:10.1021/acsanm.8b02056 · Cited by 52
Colak, B., & Ertas, Y. N. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c17024 · Cited by 50
Nanoparticle delivery in vivo: A fresh look from intravital imaging
Lin, Q., Fathi, P., & Chen, X. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102958 · Cited by 48
Recent developments in nanomaterial-based shear-sensitive drug delivery systems
Wang, Y., Pisapati, A. V., Zhang, X. F., & Cheng, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002196 · Cited by 44
Surface enhanced deep Raman detection of cancer tumour through 71 mm of heterogeneous tissue
Dey, P., Vaideanu, A., Mosca, S., Salimi, M., Gardner, B., Palombo, F., Uchegbu, I., Baumberg, J., Schatzlein, A., Matousek, P., et al. (2022) · Nanotheranostics · doi:10.7150/ntno.71510 · Cited by 34
Cui, H., Su, Y., Wei, W., Xu, F., Gao, J., & Zhang, W. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s368763 · Cited by 32
Park, J., Pei, Y., Hyun, H., Castanares, M. A., Collins, D. S., & Yeo, Y. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.037 · Cited by 29
Lee, K., Gao, Y., Chou, S., Wan, Y., Hsu, A. C., Tan, J., Li, Y., Guan, Z., Chen, H., Li, S., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202407317 · Cited by 27
Chen, G., He, P., Ma, C., Xu, J., Su, T., Wen, J., Kuo, H.-C., Jing, L., Chen, S.-L., & Tu, C.-C. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c10800 · Cited by 19
High-resolution 3D visualization of nanomedicine distribution in tumors
Moss, J. I., Barjat, H., Emmas, S.-A., Strittmatter, N., Maynard, J., Goodwin, R. J. A., Storm, G., Lammers, T., Puri, S., Ashford, M. B., et al. (2020) · Theranostics · doi:10.7150/thno.37178 · Cited by 19
He, J., Xue, W., & Li, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s560983 · Cited by 16
Drug Delivery Based on Nanotechnology for Target Bone Disease
Yang, X., Chen, S., Liu, X., Yu, M., & Liu, X. (2019) · Current Drug Delivery · doi:10.2174/1567201816666190917123948 · Cited by 15
Assessing the benefits of drug delivery by nanocarriers: a partico/pharmacokinetic framework
Siegel, R. A., Kirtane, A. R., & Panyam, J. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2632733 · Cited by 14
Metadata
- Authors
- Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W.
- Affiliations
- University of Toronto (CA)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Chan, Warren C. W.
- Venue
- Nature Reviews Materials
- Published
- 2016-04-26
- Volume
- 1
- Issue
- 5
- ISSN
- 2058-8437 (ISSN-L)
- OpenAlex
- W2344644350
- Semantic Scholar
- 24242bb923442a41c77ab81c413e0c3db3a41ba9
- Cited by
- 5,218
- References
- 125
- Citations by year
- 2026: 629 · 2025: 481 · 2024: 495 · 2023: 486 · 2022: 568 · 2021: 616 · 2020: 642 · 2019: 525 · 2018: 423 · 2017: 272 · 2016: 79
- FWCI
- 23.22
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- Nature Reviews Materials (publishedVersion)
- TSpace (University of Toronto) (submittedVersion)
- Funders
- Prostate Cancer Canada
- Ministry of Education, Culture, Sports, Science and Technology (26820356)
- National Institutes of Health (CA92644)
- Japan Society for the Promotion of Science (26820356)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- tumor targeting, nanomedicine, tumor stroma, enhanced permeability and retention effect, tumor models, cancer types, reticuloendothelial system, renal clearance, clinical translation of nanomedicine, tumor accumulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
